Su et al. reported that FGFR2 amplification was more frequently observed in gastric cancer patients with a higher N stage and poorly differentiated histology [22]; these factors are considered to contribute to the development of recurrence and poor prognosis in FGFR2-amplified resectable gastric cancer. The gene discussed is FGFR2; the disease is gastric cancer.